LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8⁺ T Cells.

ABSTRACT: Elicitation of tumor cell killing by CD8⁺ T cells is an effective therapeutic approach for cancer. In addition to using immune checkpoint blockade to reinvigorate existing but unresponsive tumor-specific T cells, alternative therapeutic approaches have been developed, including stimulation of polyclonal T cell cytolytic activity against tumors using bispecific T cell engager (BiTE) molecules that simultaneously engage the TCR complex and a tumor-associated Ag. BiTE molecules are efficacious against hematologic tumors and are currently being explored as an immunotherapy for solid tumors. To understand mechanisms regulating BiTE molecule--mediated CD8⁺ T cell activity against solid tumors, we sought to define human CD8⁺ T cell populations that efficiently res

SUBMITTER: Kim A 

PROVIDER: S-EPMC6680066 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature